Loading...
•
Mar 31, 2022
Reviva Q1 2022 Earnings Report
Reported first quarter 2022 financial results and recent business highlights.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of approximately $7.4 million, or $0.40 per share, for the three months ended March 31, 2022. As of March 31, 2022, the Company’s cash totaled approximately $23.4 million.
Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders.
Dosed first patient in pivotal Phase 3 RECOVER study in Feburary to assess the safety and efficacy in patients with schizophrenia
Initiated more than a dozen sites across the US, with additional international sites on schedule to launch later this summer in both India and Europe.
Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023
Forward Guidance
May initiate Phase 2a studies in bipolar disorder, major depressive disorder (MDD), attention deficit hyperactive disorder (ADHD), pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) subject to the receipt of additional financing.
Positive Outlook
- Advance clinical development of Reviva’s lead asset, brilaroxazine
- Initiate Phase 2a studies in bipolar disorder, major depressive disorder (MDD), attention deficit hyperactive disorder (ADHD), pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) subject to the receipt of additional financing
- Pursue strategic partnership opportunities for the development of our pipeline
- Evaluate grant and other non-dilutive financing opportunities for product candidates from Federal and State Healthcare Agencies and Foundations
- Company’s cash as of March 31, 2022 will be sufficient to fund its current operating plans through at least March 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...